Momentum for STING agonists grew after preclinical studies involving STING-deficient tumor-bearing mice were demonstrated as having fewer IFNγ-producing CD8+ T cells with increased Tregs and MDSCs [312]. This evidence concerns the gene STING1 and neoplasm.